Lim Kook Jin, Park Jea Won, Yeom Joon-Sup, Lee Young-Ha, Yoo Seung Bum, Oh Jae Hoon, Sohn Mi Jin, Bahk Young Yil, Kim Yu Sam
Protein Network Research Center, Department of Biochemistry, College of Science, Yonsei University, 120-749 Seoul, Korea.
Parasitol Res. 2004 Mar;92(5):384-9. doi: 10.1007/s00436-003-1009-0. Epub 2004 Jan 27.
Most people infected with Plasmodium vivax malaria developed antibodies against the C-terminal region of P. vivax merozoite surface protein (PvMSP1c) and the antibodies are sustained for a period up to 10 months after anti-malarial treatment. The longer-term stability of the specific humoral response was evaluated indirectly by determining the antibody titers in the sera from healthy individuals who lived an area from which malaria had been eradicated (450 persons) and an area in which it had recurred (1,524 persons). There were considerable residual antibody responses to PvMSP1c in over 15% of sera from healthy individuals, but only those who had lived in the era when malaria was prevalent. This means that antibodies against PvMSP1c may persist for more than 30 years, the malaria-free duration. This long-term memory of humoral immunity supports the C-terminal region of merozoite surface protein 1 as an effective malaria vaccine, in addition to the neutralizing activity reported previously.
大多数感染间日疟原虫疟疾的人会产生针对间日疟原虫裂殖子表面蛋白（PvMSP1c）C端区域的抗体，且这些抗体在抗疟治疗后可持续长达10个月。通过测定来自疟疾已根除地区（450人）和疟疾复发地区（1524人）的健康个体血清中的抗体滴度，间接评估了特异性体液反应的长期稳定性。在超过15%的健康个体血清中，对PvMSP1c存在相当程度的残留抗体反应，但只有那些曾生活在疟疾流行时代的个体才有。这意味着针对PvMSP1c的抗体可能持续超过30年，即无疟疾持续时间。除了先前报道的中和活性外，这种体液免疫的长期记忆支持裂殖子表面蛋白1的C端区域作为一种有效的疟疾疫苗。
